Loading clinical trials...
Loading clinical trials...
Transjugular liver catheterisation allows the measurement of hepatic venous pressure gradient (HVPG) and the sampling of liver tissue but patient's tolerance to the procedure is unknown. The aim of this study was to assess tolerance to transjugular hepatic liver biopsy with or without conscious sedation/analgesia.
Consecutive patients undergoing transjugular liver biopsy will be randomly assigned to receive either placebo or midazolam (0.02 mg/kg) or 0.02 mg/kg midazolam combined with 1 mg/kg pethidine before the procedure.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Hopital Erasme - Dpt of Gastroenterology
Brussels, Belgium
Start Date
May 1, 2003
Primary Completion Date
October 1, 2005
Completion Date
October 1, 2005
Last Updated
January 17, 2008
180
ACTUAL participants
transjugular liver biopsy
PROCEDURE
placebo
DRUG
midazolam
DRUG
midazolam + pethidine
DRUG
Lead Sponsor
Erasme University Hospital
NCT05597488
NCT07478393
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07456631